Bogaert M G
Heymans Institute of Pharmacology, Gent University Medical School, Belgium.
Drugs. 1996;52 Suppl 4:3-7; discussion 7-8. doi: 10.2165/00003495-199600524-00004.
The calcium channel blockers (calcium antagonists) have vasodilatory and cardiodepressant effects. These pharmacological properties explain, to a large extent, the antihypertensive, antianginal, and antiarrhythmic effects of these agents. Pharmacological differences between members of this class, e.g. differences in vascular selectivity, are well documented and can be exploited clinically. The efficacy of calcium channel blockers in the prevention of cardiovascular events may depend on factors other than their vasodilatory and cardiodepressive effects. Much interest, for example, has been shown in their possible antiatherosclerotic effects. It is, however, at present not possible to ascertain how important these and other ancillary effects (such as plaque stabilisation) are for the putative cardioprotective effects of calcium channel blockers. There are, moreover, few in vitro or in vivo (animal or clinical) studies allowing valid comparison of the different calcium channel blockers with regard to these ancillary properties.
钙通道阻滞剂（钙拮抗剂）具有血管舒张和心脏抑制作用。这些药理特性在很大程度上解释了这些药物的抗高血压、抗心绞痛和抗心律失常作用。该类药物成员之间的药理差异，如血管选择性差异，已有充分记录且可在临床上加以利用。钙通道阻滞剂预防心血管事件的疗效可能取决于其血管舒张和心脏抑制作用之外的其他因素。例如，人们对其可能的抗动脉粥样硬化作用表现出了浓厚兴趣。然而，目前尚无法确定这些及其他辅助作用（如斑块稳定作用）对于钙通道阻滞剂假定的心脏保护作用有多重要。此外，很少有体外或体内（动物或临床）研究能够就这些辅助特性对不同钙通道阻滞剂进行有效的比较。
